Zürich (ots) - Zartes Licht, weiche Haut, reizender Stoff: Mit grossflächigen Kampagnen startet die ...
Unilabs reaffirms its growth objectives for 2004/2005
During the first quarter, Unilabs laboratories achieved:
- revenues of CHF 54.8 million (+4.7%)
- EBITDA margin of CHF 6.2 million (+18.6%)
- EBIT margin of CHF 4.1 million (+29.3%)
Geneva (ots) - During the first quarter of the 2004/2005 fiscal year, which ended on 31 August 2004, Unilabs laboratories achieved consolidated revenues of CHF 54.8 million, up 4.7% as compared to the same prior year period, or 5.1% at constant exchange rates comprising 4.8% internal growth. EBITDA margin of the period was CHF 6.2 million, up 18.6%. Due to the adoption as of 1 June 2004 of the new IAS standards governing goodwill accounting, the EBIT margin for the period reached CHF 4.1 million, up 29.3% when compared to CHF 3.1 million for the same period of the preceding year as restated on a comparable accounting principle.
The first quarter of the fiscal year is not deemed to be representative of annual results. Nevertheless, Unilabs management believes that such results comfort its trust as to its ability of reaching its internal growth objective for the current fiscal year 2004/2005, that is 4.5%.
The Unilabs Group (SWX: ULB) is the European leader of
laboratories for medical analyses. With 41 laboratories and over 1500
employees operating in 5 countries, Unilabs analyses over 3.5 million
samples per year using a panel of more than 1500 clinical tests. The
medical analyses of Unilabs are used by 60 hospitals in France, Spain
and Switzerland. Unilabs is listed on the SWX Swiss Stock Exchange
Our press releases are also available on our web site (www.unilabs.com).
ots Originaltext: Unilabs SA